Further advances in cancer immunotherapy: Going beyond checkpoint blockade

Frontiers in Immunology

Volumn 9, Issue JUN, 2018, Pages

  Wilkinson, Robert W ^a   Leishman, Andrew J ^a,b  

^a MEDIMMUNE LTD   (United Kingdom)

^b Immunoconsulting Limited   (United Kingdom)

Author keywords

Immuno oncology; Immunotherapy; Oncology; Toll like receptors; Tumour microenvironment

Indexed keywords

DURVALUMAB; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; IPILIMUMAB; NIVOLUMAB; OLECLUMAB; PEMBROLIZUMAB; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; PALLIATIVE THERAPY; PROTEIN EXPRESSION; SHORT SURVEY; SOMATIC MUTATION; TUMOR MICROENVIRONMENT;

EID: 85047865218     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01082     Document Type: Short Survey

References (14)

1. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol (2016) 39(1):98-106. doi:10.1097/COC.0000000000000239
2. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol (2016) 34(26):3119-25. doi:10.1200/JCO.2016.67.9761
3. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12(4):298-306. doi:10.1038/nrc3245
4. Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med (2016) 14:273. doi:10.1186/s12967-016-1029-z
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139
6. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515(7528):568-71. doi:10.1038/nature13954
7. Higgs BW, Robbins PB, Blake-Haskins JA, Zhu W, Morehouse C, Brohawn PZ, et al. High tumoral IFN? mRNA, PD-L1 protein, and combined IFN? mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. Eur J Cancer (2015) 51(Suppl 3):S717, 15LBA. doi:10.1016/S0959-8049(16)31937-2
8. Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res (2017) 5(1):29-41. doi:10.1158/2326-6066.CIR-16-0114
9. Mullins SR, Vogel K, Vasilako J, Grigsby I, Dovedi S, Ryan P, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors. American Association for Cancer Research 110th Annual Meeting. Washington, DC (2017). Proc Am Assoc Cancer Res 2017: abst 4697
10. Gupta S, Grilley-Olson J, Hong D, Marabelle A, Munster P, Aggarwal R, et al. Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. American Association for Cancer Research 110th Annual Meeting. Washington, DC (2017). Proc Am Assoc Cancer Res 2017: abst CT091
11. Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology (2016) 5(8):e1208875. doi:10.1080/2162402X.2016.1208875
12. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell (2016) 30(3):391-403. doi:10.1016/j.ccell.2016.06.025
13. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-3. doi:10.1126/science.281.5380.1191
14. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol (2016) 37:193-207. doi:10.1016/j.it.2016.01.002